{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T17:51:40Z","timestamp":1776275500244,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Antibiot"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1038\/ja.2015.120","type":"journal-article","created":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T07:20:27Z","timestamp":1449040827000},"page":"381-387","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["In vitro activity of dalbavancin and five comparator agents against common and uncommon Gram-positive organisms isolated from cancer patients"],"prefix":"10.1038","volume":"69","author":[{"given":"Kenneth V I","family":"Rolston","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiqun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lior","family":"Nesher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel A","family":"Shelburne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randall A","family":"Prince","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,2]]},"reference":[{"key":"BFja2015120_CR1","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1086\/374339","volume":"36","author":"H Wisplinghoff","year":"2003","unstructured":"Wisplinghoff, H., Seifert, H., Wenzel, R. P. & Edmond, M. B. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin. Infect. Dis. 36, 1103\u20131110 (2003).","journal-title":"Clin. Infect. Dis."},{"issue":"Suppl 1","key":"BFja2015120_CR2","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1016\/j.ijantimicag.2007.06.012","volume":"30","author":"J Klastersky","year":"2007","unstructured":"Klastersky, J. et al. Bacteraemia in febrile neutropenic cancer patients. Int. J. Antimicrob. Agents 30 (Suppl 1), S51\u2013S59 (2007).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"BFja2015120_CR3","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/cid\/cir492","volume":"53","author":"A Safdar","year":"2011","unstructured":"Safdar, A. & Armstrong, D. Infections in patients with hematologic neoplasms and hematopoietic stem cell transplantation: neutropenia, humoral, and splenic defects. Clin. Infect. Dis. 53, 798\u2013806 (2011).","journal-title":"Clin. Infect. Dis."},{"key":"BFja2015120_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s15010-013-0525-9","volume":"42","author":"L Nesher","year":"2014","unstructured":"Nesher, L. & Rolston, K. V. The current spectrum of infection in cancer patients with chemotherapy related neutropenia. Infection 42, 5\u201313 (2014).","journal-title":"Infection"},{"key":"BFja2015120_CR5","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ijantimicag.2013.01.014","volume":"41","author":"KV Rolston","year":"2013","unstructured":"Rolston, K. V., Kapadia, M., Tarrand, J., Coyle, E. & Prince, R. A. Spectrum of gram-positive bacteraemia and in vitro activities of daptomycin, linezolid and vancomycin against organisms isolated from cancer patients. Int. J. Antimicrob. Agents 41, 516\u2013520 (2013).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"BFja2015120_CR6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1086\/518873","volume":"45","author":"KV Rolston","year":"2007","unstructured":"Rolston, K. V., Bodey, G. P. & Safdar, A. Polymicrobial infection in patients with cancer: an underappreciated and underreported entity. Clin. Infect. Dis. 45, 228\u2013233 (2007).","journal-title":"Clin. Infect. Dis."},{"issue":"Suppl 1","key":"BFja2015120_CR7","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1086\/491708","volume":"42","author":"RC Moellering Jr","year":"2006","unstructured":"Moellering, R. C. Jr . Vancomycin: a 50-year reassessment. Clin. Infect. Dis. 42 (Suppl 1), S3\u2013S4 (2006).","journal-title":"Clin. Infect. Dis."},{"key":"BFja2015120_CR8","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld, A. G. et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin. Infect. Dis. 52, e56\u2013e93 (2011).","journal-title":"Clin. Infect. Dis."},{"key":"BFja2015120_CR9","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1128\/JCM.42.6.2398-2402.2004","volume":"42","author":"G Sakoulas","year":"2004","unstructured":"Sakoulas, G. et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42, 2398\u20132402 (2004).","journal-title":"J. Clin. Microbiol."},{"key":"BFja2015120_CR10","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1002\/cncr.21801","volume":"106","author":"A Safdar","year":"2006","unstructured":"Safdar, A. & Rolston, K. V. Vancomycin tolerance, a potential mechanism for refractory gram-positive bacteremia observational study in patients with cancer. Cancer 106, 1815\u20131820 (2006).","journal-title":"Cancer"},{"key":"BFja2015120_CR11","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1093\/jac\/dkm258","volume":"60","author":"G Steinkraus","year":"2007","unstructured":"Steinkraus, G., White, R. & Friedrich, L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J. Antimicrob. Chemother. 60, 788\u2013794 (2007).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFja2015120_CR12","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1086\/605636","volume":"49","author":"SK Pillai","year":"2009","unstructured":"Pillai, S. K. et al. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus. Clin. Infect. Dis. 49, 1169\u20131174 (2009).","journal-title":"Clin. Infect. Dis."},{"key":"BFja2015120_CR13","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1086\/421092","volume":"38","author":"PA Moise-Broder","year":"2004","unstructured":"Moise-Broder, P. A. et al. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin. Infect. Dis. 38, 1700\u20131705 (2004).","journal-title":"Clin. Infect. Dis."},{"key":"BFja2015120_CR14","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1086\/513203","volume":"44","author":"FC Tenover","year":"2007","unstructured":"Tenover, F. C. & Moellering, R. C. Jr . The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin. Infect. Dis. 44, 1208\u20131215 (2007).","journal-title":"Clin. Infect. Dis."},{"key":"BFja2015120_CR15","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/cid\/cir935","volume":"54","author":"SJ van Hal","year":"2012","unstructured":"van Hal, S. J., Lodise, T. P. & Paterson, D. L. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin. Infect. Dis. 54, 755\u2013771 (2012).","journal-title":"Clin. Infect. Dis."},{"key":"BFja2015120_CR16","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1634\/theoncologist.2012-0029","volume":"17","author":"SN Mahajan","year":"2012","unstructured":"Mahajan, S. N. et al. Characteristics and outcomes of methicillin-resistant staphylococcus aureus bloodstream infections in patients with cancer treated with vancomycin: 9-year experience at a comprehensive cancer center. Oncologist 17, 1329\u20131336 (2012).","journal-title":"Oncologist"},{"key":"BFja2015120_CR17","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/cid\/cir034","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu, C. et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin. Infect. Dis. 52, 285\u2013292 (2011).","journal-title":"Clin. Infect. Dis."},{"key":"BFja2015120_CR18","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1086\/500139","volume":"42","author":"B Jaksic","year":"2006","unstructured":"Jaksic, B. et al. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin. Infect. Dis. 42, 597\u2013607 (2006).","journal-title":"Clin. Infect. Dis."},{"key":"BFja2015120_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00520-013-1947-8","volume":"22","author":"KV Rolston","year":"2014","unstructured":"Rolston, K. V. et al. Daptomycin use in neutropenic patients with documented gram-positive infections. Support Care Cancer 22, 7\u201314 (2014).","journal-title":"Support Care Cancer"},{"key":"BFja2015120_CR20","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/ja.2014.30","volume":"67","author":"Kt Rolston","year":"2014","unstructured":"Rolston, K. t. et al. In vitro activity of telavancin compared with vancomycin and linezolid against Gram-positive organisms isolated from cancer patients. J. Antibiot. (Tokyo) 67, 505\u2013509 (2014).","journal-title":"J. Antibiot. (Tokyo)"},{"key":"BFja2015120_CR21","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.diagmicrobio.2010.10.031","volume":"69","author":"JA Karlowsky","year":"2011","unstructured":"Karlowsky, J. A. et al. In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study. Diagn. Microbiol. Infect. Dis. 69, 342\u2013347 (2011).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"BFja2015120_CR22","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.diagmicrobio.2013.01.002","volume":"76","author":"RN Jones","year":"2013","unstructured":"Jones, R. N. & Stilwell, M. G. Comprehensive update of dalbavancin activity when tested against uncommonly isolated streptococci, Corynebacterium spp., Listeria monocytogenes, and Micrococcus spp. (1357 strains). Diagn. Microbiol. Infect. Dis. 76, 239\u2013240 (2013).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"BFja2015120_CR23","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.diagmicrobio.2012.11.024","volume":"75","author":"RN Jones","year":"2013","unstructured":"Jones, R. N., Sader, H. S. & Flamm, R. K. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011). Diagn. Microbiol. Infect. Dis. 75, 304\u2013307 (2013).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"BFja2015120_CR24","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s10096-013-1819-7","volume":"32","author":"E Montassier","year":"2013","unstructured":"Montassier, E., Batard, E., Gastinne, T., Potel, G. & de La Cocheti\u00e8re, M. F. Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. Eur. J. Clin. Microbiol. Infect. Dis. 32, 841\u2013850 (2013).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"BFja2015120_CR25","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1086\/513764","volume":"25","author":"WT Hughes","year":"1997","unstructured":"Hughes, W. T. et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin. Infect. Dis. 25, 551\u2013573 (1997).","journal-title":"Clin. Infect. Dis."},{"key":"BFja2015120_CR26","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1086\/425009","volume":"39","author":"RW Finberg","year":"2004","unstructured":"Finberg, R. W. et al. The importance of bactericidal drugs: future directions in infectious disease. Clin. Infect. Dis. 39, 1314\u20131320 (2004).","journal-title":"Clin. Infect. Dis."},{"key":"BFja2015120_CR27","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s40121-014-0048-4","volume":"3","author":"KV Rolston","year":"2014","unstructured":"Rolston, K. V., Nesher, L. & Tarrand, J. T. Current microbiology of surgical site infections in patients with cancer: a retrospective review. Infect. Dis. Ther. 3, 245\u2013256 (2014).","journal-title":"Infect. Dis. Ther."},{"key":"BFja2015120_CR28","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1128\/AAC.46.8.2723-2726.2002","volume":"46","author":"SL Gerson","year":"2002","unstructured":"Gerson, S. L. et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob. Agents Chemother. 46, 2723\u20132726 (2002).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja2015120_CR29","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/jac\/dks354","volume":"68","author":"B Gu","year":"2013","unstructured":"Gu, B., Kelesidis, T., Tsiodras, S., Hindler, J. & Humphries, R. M. The emerging problem of linezolid-resistant Staphylococcus. J. Antimicrob. Chemother. 68, 4\u201311 (2013).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFja2015120_CR30","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.1128\/AAC.00274-15","volume":"59","author":"SP McCurdy","year":"2015","unstructured":"McCurdy, S. P., Jones, R. N., Mendes, R. E., Puttagunta, S. & Dunne, M. W. In vitro activity of dalbavancin against drug-resistant Staphylococcus aureus Isolates from a Global Surveillance Program. Antimicrob. Agents Chemother. 59, 5007\u20135009 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja2015120_CR31","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","volume":"370","author":"HW Boucher","year":"2014","unstructured":"Boucher, H. W. et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N. Engl. J. Med. 370, 2169\u20132179 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFja2015120_CR32","unstructured":"Two new drugs for skin and skin structure infections. Med. Lett. Drugs Ther. 56, 73\u201375 (2014)."},{"key":"BFja2015120_CR33","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1086\/427283","volume":"40","author":"I Raad","year":"2005","unstructured":"Raad, I. et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin. Infect. Dis. 40, 374\u2013380 (2005).","journal-title":"Clin. Infect. Dis."},{"key":"BFja2015120_CR34","doi-asserted-by":"crossref","unstructured":"Dunne, M. et al Single Dose Treatment with Dalbavancin for Acute Bacterial Skin and Skin Structure Infection (ID Week, San Diego, CA, USA, (2015).","DOI":"10.1093\/ofid\/ofv133.502"},{"issue":"Suppl 2","key":"BFja2015120_CR35","doi-asserted-by":"publisher","first-page":"ii25","DOI":"10.1093\/jac\/dki008","volume":"55","author":"MB Dorr","year":"2005","unstructured":"Dorr, M. B. et al. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J. Antimicrob. Chemother. 55 (Suppl 2), ii25\u2013ii30 (2005).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFja2015120_CR36","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1128\/AAC.48.3.940-945.2004","volume":"48","author":"A Leighton","year":"2004","unstructured":"Leighton, A. et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob. Agents Chemother. 48, 940\u2013945 (2004).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja2015120_CR37","unstructured":"Clinical and Laboratory Standards Institute (CLSI) Performance Standards for Antimicrobial Susceptibility Testing, (CLSI, Wayne, PA, (2014)."}],"container-title":["The Journal of Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ja2015120.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ja2015120","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ja2015120.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:22:03Z","timestamp":1684430523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ja2015120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,2]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["BFja2015120"],"URL":"https:\/\/doi.org\/10.1038\/ja.2015.120","relation":{},"ISSN":["0021-8820","1881-1469"],"issn-type":[{"value":"0021-8820","type":"print"},{"value":"1881-1469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,2]]},"assertion":[{"value":"24 August 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}